Inhibikase Therapeutics Inc SEC Filings

Inhibikase Therapeutics director Aurentz Vincent reported beneficial ownership of 765,895 shares of common stock in an amended Form 3/A. These shares were issued as merger consideration in connection with the acquisition of CorHepta Pharmaceuticals completed on 02/21/2025 and were added to an earlier Form 3 filed 02/25/2025.

Of the 765,895 shares, 127,649 vested on the closing date, 382,947 will vest on the first anniversary of the closing date, and 255,299 are contingent: 25% of that tranche vests upon achievement of a specified milestone and 75% vests on the first anniversary, subject to continued service; if the milestone is not achieved by the first anniversary, all 255,299 shares are forfeited.

Insider share issuance tied to acquisition: This Form 4 shows director Amit Munshi received 57,265 shares of Inhibikase Therapeutics, Inc. (IKT) on 02/21/2025 as merger consideration for the acquisition of CorHepta Pharmaceuticals, Inc. Of those shares, 9,544 vested immediately on closing and 28,632 are scheduled to vest on the first anniversary of the closing. The remaining 19,089 shares are subject to a milestone-based vesting condition: 25% of that portion vests if a specified milestone is achieved and 75% vests on the first anniversary of closing, provided the reporting person continues service; if the milestone is not achieved by the first anniversary, all 19,089 shares are forfeited. The Form also discloses Mr. Munshi beneficially owns 365,000 shares indirectly through the Amit Munshi Revocable Trust. The filing is signed by an attorney-in-fact on 08/28/2025.

ADAR1 entities and manager Daniel Schneeberger report collectively holding 7,682,503 to 7,737,694 shares of Inhibikase Therapeutics, Inc. (IKT), representing 9.9% of the outstanding common stock as of June 30, 2025. The filing breaks down holdings across ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; and ADAR1 SPV I, LP, and includes both issued shares and shares underlying milestone warrants. The filing also discloses that additional milestone warrants (several million shares) are excluded from beneficial ownership calculations because their exercise or exchange is subject to a 9.99% ownership limitation. The report is filed under Schedule 13G/A and is signed by Daniel Schneeberger as manager and in his individual capacity.

Inhibikase Therapeutics (IKT) reported items in its Form 10-Q showing corporate and development activity ahead of a planned Phase 2b study in pulmonary arterial hypertension (PAH). The company expects to initiate a ~150‑patient Phase 2b trial in the second half of 2025 and used non‑human primate safety studies and a bioequivalence trial in healthy volunteers to set dosing.

Financing and equity actions are material: a private placement included issuance of shares and multiple warrant tranches exercisable at $1.37 and $1.49 with exercise and ownership caps, and 19,665,131 pre‑funded warrants were outstanding at June 30, 2025. An at‑the‑market agreement with HCW was terminated effective December 11, 2024; a separate Sales Agreement with Jefferies and a related shelf registration were in place as of June 27, 2025. The company acquired CorHepta, issuing shares including contingent and performance‑based shares and recognized a $7,357,294 R&D write‑off related to IPR&D.

This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.

The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.

Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.